GLP-1 receptor agonism ameliorates Parkinsons disease through modulation of neuronal insulin signalling and glial suppression
Dilan S. Athauda, James R Evans, Laura Mahoney‐Sanchez, Gurvir S. Virdi, Patricia Lopez-Garcia, Anna I. Wernick, Aaron Z. Wagen, Karishma D’Sa, Joanne Lachica, Stephanie Strohbuecker, Giulia Vecchi, Craig Leighton, Rebecca S. Saleeb, Judi O’Shaughnessy, Christina E. Toomey, , Sonia Gandhi
This study shows GLP-1R agonism improves Parkinson's disease by restoring neuronal insulin signaling and reducing glial inflammation, with clinical benefits in patients with higher baseline MAPK expression.
bioRxiv · Feb 28, 2024 · PreprintNeuroscience